Session » SLE – Diagnosis, Manifestations, & Outcomes Poster II

Date: Sunday, November 17, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 1484

A Retrospective Evaluation of Glucagon-like Peptide-1 Receptor Agonists in SLE Patients

10:30AM-12:30PM: Abstract Number: 1513

Assessing Subjective Cognitive Impairment in a Cohort of Canadian Systemic Lupus Erythematosus Patients: Construct Validity of PDQ-20

10:30AM-12:30PM: Abstract Number: 1512

Association Between the Systemic Immune Inflammatory Index (Sll) and All-cause Mortality in Critically Ill Patients with Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 1530

Belimumab-Treated Patients with Systemic Lupus Erythematosus Without Prior Immunosuppressant Use Have More Favorable Clinical Outcomes Than Those with Prior Use of an Immunosuppressant

10:30AM-12:30PM: Abstract Number: 1486

Cardiovascular Risk in Systemic Lupus Erythematosus: Carotid Ultrasonography Is Useful for the Re-stratification of Cardiovascular Risk Determined by Score2

10:30AM-12:30PM: Abstract Number: 1508

Clinical Characteristics and Prognosis of Late-onset Systemic Lupus Erythematosus in 305 Japanese Patients

10:30AM-12:30PM: Abstract Number: 1488

Clinical Utility and Performance of Anti-C1q Antibodies for Systemic Lupus Erythematosus: Comparative Analysis of Three Different Assays

10:30AM-12:30PM: Abstract Number: 1506

Cognitive Impairment Prevalence and Most Affected Domains in Patients with SLE by the ACR Comprehensive Neuropsychological Battery

10:30AM-12:30PM: Abstract Number: 1527

Comparative Harms in Patients with Systemic Lupus Erythematosus Treated with Anifrolumab or Belimumab: A Multicenter Cohort Study Using the TriNetX Research Network

10:30AM-12:30PM: Abstract Number: 1521

Contemporary Lupus Nephritis Treatment and Outcomes Among Patients with Systemic Lupus Erythematosus in the United States

10:30AM-12:30PM: Abstract Number: 1517

Diagnostic Performance of Anti-dsDNA Antibodies in Pleural, Ascitic and Pericardial Fluid for Lupus Serositis: Experience of a Tertiary Center in Mexico

10:30AM-12:30PM: Abstract Number: 1516

Diagnostic Performance of Anti-ribosomal P Antibodies in Cerebrospinal Fluid of Neuropsychiatric Systemic Lupus Erythematosus with Diffuse Central Nervous System Manifestations. Experience in a Tertiary Center in Mexico

10:30AM-12:30PM: Abstract Number: 1496

Dysregulated Serum Cytokines in Association with Clinical Manifestations in Patients with Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 1525

Early versus Late Lupus Nephritis: A Meta-analysis of Observational Studies

10:30AM-12:30PM: Abstract Number: 1498

Gender Disparities in Clinical Manifestations and Outcomes of Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis

10:30AM-12:30PM: Abstract Number: 1485

Genetic Contributions to Systemic Lupus Erythematosus: Concordance Rates in California Twins

10:30AM-12:30PM: Abstract Number: 1493

How Do Lupus Nephritis Patients Who Achieve Renal Remission Fare? A 3-year Comparison in Terms of GFR Decline

10:30AM-12:30PM: Abstract Number: 1514

Immunosenescent and Exhausted T Cells in Patients with Systemic Lupus Erythematosus and Cognitive Impairment

10:30AM-12:30PM: Abstract Number: 1510

Impact of Active Lupus Nephritis on the Quality of Life of Patients from a Latin American Lupus Cohort

10:30AM-12:30PM: Abstract Number: 1522

Impact of Thrombocytopenia on In-hospital Mortality and Healthcare Resource Utilization in Patients with Systemic Lupus Erythematosus: An Analysis of the National Inpatient Sample Database 2020

10:30AM-12:30PM: Abstract Number: 1515

Incidence and Predictors of Neuropsychiatric Lupus—a Contemporary Cohort Study Across the United States

10:30AM-12:30PM: Abstract Number: 1505

Incidence of Cardiovascular and Venous Thromboembolic Events in Four Autoantibody-defined Systemic Lupus Erythematosus Clusters

10:30AM-12:30PM: Abstract Number: 1519

Incidence, Risk Factors, and Outcomes of Severe Lymphopenia in Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 1511

Lupus Nephritis and Response to Treatment in Latin America

10:30AM-12:30PM: Abstract Number: 1489

Lupus Nephritis Clinical and Serological Responses at 12 Months: Implications for Repeat Biopsy, Intensified Immunosuppression or Additional Anti-proteinuric Therapy

10:30AM-12:30PM: Abstract Number: 1490

Multi-centered Clinical Validation of T Cell-bound C4d (TC4d) and T Cell Autoantibodies (TIgG and TIgM): Sensitive and Specific Biomarkers of SLE with Enhanced Accuracy Compared to Conventional SLE Tests

10:30AM-12:30PM: Abstract Number: 1504

Novel Analytes Associated with Cognitive Impairment in Patients with Systemic Lupus Erythematosus: Serum S100A8/A9, MMP-9 and IL-6

10:30AM-12:30PM: Abstract Number: 1499

Outcome of Newly Onset SLE with Neuropsychiatric Symptoms and Its Clinical Features in Daily Clinical Practice: A Single Center Study

10:30AM-12:30PM: Abstract Number: 1518

Predictive Value of Chronic Histologic Changes in Lupus Nephritis

10:30AM-12:30PM: Abstract Number: 1487

Pregnancy Outcome and Risk Factors Analysis in Patients with Systemic Lupus Erythematosus Complicated with Thrombocytopenia

10:30AM-12:30PM: Abstract Number: 1528

Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: National Inpatient Sample Analysis

10:30AM-12:30PM: Abstract Number: 1483

Real World Data on Infections from the Indian SLE Inception Cohort for Research (INSPIRE): Spectrum and Risk Factors

10:30AM-12:30PM: Abstract Number: 1495

Real-World Reduction in Disease Flares and Oral Corticosteroid Use with Anifrolumab Therapy in Systemic Lupus Erythematosus: A Claims-Based Study

10:30AM-12:30PM: Abstract Number: 1501

Retrospective Cohort Study Identifying Pulmonary Complications in a Cohort of Patients with Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 1491

Self-Reported Cognitive Function Among Older Adults with Systemic Lupus Erythematosus (SLE) Compared to Older Adults with Other Rheumatic and Musculoskeletal Conditions

10:30AM-12:30PM: Abstract Number: 1503

Social Connections Among Middle-Aged and Older Adults with Systemic Lupus Erythematosus: A Single Center Cross-Sectional Study

10:30AM-12:30PM: Abstract Number: 1529

Systemic Lupus Erythematous and Neuromyelitis Optica Overlap and Risk of Infection in Hospitalized Patients

10:30AM-12:30PM: Abstract Number: 1520

The Influence of Trauma on Features of Type 2 SLE

10:30AM-12:30PM: Abstract Number: 1502

The Systemic Lupus International Collaborating Clinics (SLICC) Frailty Index (SLICC-FI) Predicts Hospitalizations. Data from the Almenara Lupus Cohort

10:30AM-12:30PM: Abstract Number: 1524

Thrombocytopenia and Systemic Lupus Erythematosus: A Meta-analysis of Observational Studies

10:30AM-12:30PM: Abstract Number: 1492

Timing of SLEDAI-2K Item Improvements During the First Year of Intravenous Anifrolumab Treatment of Moderate to Severe SLE

10:30AM-12:30PM: Abstract Number: 1507

To Develop a Method for Estimating Interferon Signatures in SLE from Routine Clinical Laboratory Tests

10:30AM-12:30PM: Abstract Number: 1494

Trajectories of Disease Evolution upon Treatment Initiation in Systemic Lupus Erythematosus: Pooled Results from Three Randomized Clinical Trials of Belimumab

10:30AM-12:30PM: Abstract Number: 1523

Trend Analysis of Lupus Nephritis Flares, Mortality, and Disparities: 2016-2020

10:30AM-12:30PM: Abstract Number: 1497

Type I Interferon Status and Clinical Manifestations in a Large Cohort of Patients with Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 1526

Utilizing Electronic Health Records to Identify Clinical Features of ANA-Positive Patients Imparting High Risk for Progression to Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 1509

Validation of a Score for the Prediction of Serious Infection in Patients with Systemic Lupus Erythematosus: Data from a Latin American Lupus Cohort

10:30AM-12:30PM: Abstract Number: 1500

Work-Related Disability and Function in Systemic Lupus Erythematosus (SLE): Outcomes of an Exploratory Study from Different Canadian Centres

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].